Dominic B Rowe

List of Publications by Year in Descending Order

80 papers	3,606 citations	28 h-index	59 g-index
85 ext. papers	4,527 ext. citations	7.3 avg, IF	4.71 L-index

#	Paper	IF	Citations
80	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS.. *Science Translational Medicine*, **2022**, 14, eabj0264	17.5	4
79	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nature Genetics*, **2021**, 53, 1636-1648	36.3	19
78	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. *Genome Biology*, **2021**, 22, 90	18.3	6
77	Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. *European Journal of Human Genetics*, **2021**,	5.3	7
76	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. *European Journal of Neurology*, **2021**, 28, 2192-2199	6	4
75	Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2021**, 101, 297.e9-297.e11	5.6	2
74	Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis. *Frontiers in Immunology*, **2021**, 12, 701550	8.4	1
73	Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis. *Journal of Proteome Research*, **2020**, 19, 3276-3285	5.6	5
72	Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis. *Npj Genomic Medicine*, **2020**, 5, 10	6.2	11
71	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 162-171	5.5	4
70	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurology, The*, **2020**, 19, 71-80	24.1	37
69	Neuronal intranuclear inclusion disease is genetically heterogeneous. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1716-1725	5.3	18
68	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. *Cell Reports*, **2020**, 33, 108323	10.6	18
67	Identity by descent analysis identifies founder events and links familial and sporadic ALS cases. *Npj Genomic Medicine*, **2020**, 5, 32	6.2	4
66	Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. *Journal of Medical Genetics*, **2020**,	5.8	16
65	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. *Journal of Parkinson's Disease*, **2019**, 9, 665-679	5.3	8
64	Monozygotic twins and triplets discordant for amyotrophic lateral sclerosis display differential methylation and gene expression. *Scientific Reports*, **2019**, 9, 8254	4.9	21

63	Limitations of Electromyography in the Assessment of Abdominal Wall Muscle Contractility Following Botulinum Toxin A Injection. *Frontiers in Surgery*, **2019**, 6, 16	2.3	9
62	The hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 310-316	3.6	12
61	Diffusion kurtosis and quantitative susceptibility mapping MRI are sensitive to structural abnormalities in amyotrophic lateral sclerosis. *NeuroImage: Clinical*, **2019**, 24, 101953	5.3	18
60	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 595-604	3.6	32
59	Whole genome sequencing for the genetic diagnosis of heterogenous dystonia phenotypes. *Parkinsonism and Related Disorders*, **2019**, 69, 111-118	3.6	24
58	Self-reported physical activity levels and clinical progression in early Parkinson□s disease. *Parkinsonism and Related Disorders*, **2019**, 61, 118-125	3.6	25
57	ISQUA18-1466Facing the Challenges of Genetic Testing: Family Member Experiences. *International Journal for Quality in Health Care*, **2018**, 30, 50-50	1.9	1
56	The Parkinson□s progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1460-1477	5.3	142
55	Inflammasome inhibition prevents □synuclein pathology and dopaminergic neurodegeneration in mice. *Science Translational Medicine*, **2018**, 10,	17.5	286
54	Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis. *Neuropharmacology*, **2017**, 112, 346-364	5.5	18
53	Motor neuron disease mortality and lifetime petrol lead exposure: Evidence from national age-specific and state-level age-standardized death rates in Australia. *Environmental Research*, **2017**, 153, 181-190	7.9	9
52	Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 475-485	3.6	16
51	Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. *Nature Communications*, **2017**, 8, 611	17.4	45
50	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nature Genetics*, **2016**, 48, 1043-8	36.3	328
49	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. *Movement Disorders*, **2016**, 31, 889-97	7	45
48	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson□s disease. *Movement Disorders*, **2015**, 30, 919-27	7	179
47	Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. *Neurobiology of Aging*, **2015**, 36, 3334.e1-3334.e5	5.6	29
46	A Temporal Association between Accumulated Petrol (Gasoline) Lead Emissions and Motor Neuron Disease in Australia. *International Journal of Environmental Research and Public Health*, **2015**, 12, 16124-35	4.6	7

45	SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. *BioMed Research International*, **2015**, 2015, 135674	3	13
44	Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurology*, **2013**, 70, 1277-87	17.2	252
43	Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. *Journal of Parkinson's Disease*, **2013**, 3, 145-52	5.3	39
42	Reduced T helper and B lymphocytes in Parkinson's disease. *Journal of Neuroimmunology*, **2012**, 252, 95-9	3.5	117
41	The phenotypic spectrum of dystonia in Mohr-Tranebjaerg syndrome. *Movement Disorders*, **2012**, 27, 1034-40	7	19
40	Adult onset leucodystrophy with neuroaxonal spheroids and pigmented glia (ALSP): report of a new kindred. *Neuropathology and Applied Neurobiology*, **2012**, 38, 95-100	5.2	4
39	Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease. *Journal of Parkinson's Disease*, **2011**, 1, 271-6	5.3	11
38	Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. *PLoS ONE*, **2011**, 6, e27041	3.7	12
37	Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. *Clinical Neurophysiology*, **2010**, 121, 1781-5	4.3	17
36	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. *Movement Disorders*, **2009**, 24, 833-8	7	52
35	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. *Movement Disorders*, **2009**, 24, 290-2	7	22
34	Anti-melanin antibodies are increased in sera in Parkinson's disease. *Experimental Neurology*, **2009**, 217, 297-301	5.7	54
33	The phase shift index for marking functional asynchrony in Alzheimer's disease patients using fMRI. *Magnetic Resonance Imaging*, **2008**, 26, 379-92	3.3	15
32	Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2008**, 147B, 495-9	3.5	12
31	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. *Movement Disorders*, **2007**, 22, 982-9	7	29
30	Characterizing phase-only fMRI data with an angular regression model. *Journal of Neuroscience Methods*, **2007**, 161, 331-41	3	16
29	Signal and noise of Fourier reconstructed fMRI data. *Journal of Neuroscience Methods*, **2007**, 159, 361-9	3	18
28	Novel prion protein gene mutation presenting with subacute PSP-like syndrome. *Neurology*, **2007**, 68, 868-70	6.5	35

27	VISA--a pass to innate immunity. *International Journal of Biochemistry and Cell Biology*, **2007**, 39, 287-91	5.6	17
26	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. *Neuroscience Letters*, **2007**, 414, 170-3	3.3	9
25	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. *Parkinsonism and Related Disorders*, **2006**, 12, 309-13	3.6	2
24	Nocturnal hypoxia in motor neuron disease is not predicted by standard respiratory function tests. *Internal Medicine Journal*, **2006**, 36, 419-22	1.6	3
23	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. *Journal of Neurochemistry*, **2005**, 95, 599-608	6	25
22	Assessment of disease progression in motor neuron disease. *Lancet Neurology, The*, **2005**, 4, 229-38	24.1	62
21	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. *Brain*, **2005**, 128, 2665-74	14.2	252
20	Interleukin-12 and interferon-gamma are not detectable in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2004**, 5, 118-20		10
19	Isolated trochlear nerve palsy as a presenting feature of primary polycythemia rubra vera. *Clinical and Experimental Ophthalmology*, **2004**, 32, 339-40	2.4	4
18	Genetic contributions to Parkinson's disease. *Brain Research Reviews*, **2004**, 46, 44-70		68
17	Eardrop attacks: seizures triggered by ciprofloxacin eardrops. *Medical Journal of Australia*, **2003**, 178, 343	4	3
16	Helicobacter pylori hiccup. *Internal Medicine Journal*, **2003**, 33, 133-4	1.6	6
15	Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. *Archives of Neurology*, **2003**, 60, 545-9		149
14	An inflammatory review of Parkinson's disease. *Progress in Neurobiology*, **2002**, 68, 325-40	10.9	267
13	Isolated fascicular oculomotor nerve palsy as the initial presentation of the antiphospholipid syndrome. *Journal of Clinical Neuroscience*, **2002**, 9, 691-4	2.2	11
12	Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. *Archives of Neurology*, **1999**, 56, 194-200		43
11	Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. *Life Sciences*, **1999**, 64, 1275-85	6.8	74
10	Right parietal cortex is involved in the perception of sound movement in humans. *Nature Neuroscience*, **1998**, 1, 74-9	25.5	238

9	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. *Journal of Neuroscience Research*, **1998**, 53, 551-8	4.4	50
8	Neurological abnormalities in familial and sporadic schizophrenia. *Brain*, **1998**, 121 (Pt 2), 191-203	11.2	80
7	Focal vertebral artery dissection causing Brown-Séquard's syndrome. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 64, 415-6	5.5	29
6	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation **1998**, 53, 551		3
5	Complications from intra-aortic balloon counterpulsation: a review of 303 cardiac surgical patients. *European Journal of Cardio-thoracic Surgery*, **1992**, 6, 530-5	3	29
4	Comparison of image analysis and flow cytometric determination of cellular DNA content. *Journal of Clinical Pathology*, **1991**, 44, 147-51	3.9	19
3	Nonrandom cosmid cloning and prophage SP beta homology near the replication terminus of the Bacillus subtilis chromosome. *Journal of Bacteriology*, **1986**, 167, 379-82	3.5	3
2	IBD analysis of Australian amyotrophic lateral sclerosis SOD1-mutation carriers identifies five founder events and links sporadic cases to existing ALS families		2
1	Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways		1